<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32692">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681081</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201400913</org_study_id>
    <nct_id>NCT02681081</nct_id>
  </id_info>
  <brief_title>Optimizing Chronic Pain Treatment With Enhanced Neuroplastic Responsiveness</brief_title>
  <acronym>OPTIMIZE</acronym>
  <official_title>Optimizing Chronic Pain Treatment With Enhanced Neuroplastic Responsiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Pain Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to identify non-invasive strategies that will optimize the
      neurobiological environment and improve learning and memory in the treatment of chronic
      pain. The overall aims of the current proposal are to determine if food restriction and/or
      glucose administration in conjunction with a relaxation/guided imagery exercise will result
      in neurophysiological changes and functional improvements compared to the relaxation/guided
      imagery exercise alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to sixty adults with chronic knee osteoarthritis pain will be randomized to one of three
      groups: food restriction (20 participants), glucose administration (20 participants), or
      control (20 participants). Participants will attend four sessions over a two to three week
      period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Neurophysiological measures</measure>
    <time_frame>baseline and 3 weeks</time_frame>
    <description>Electroencephalogram (EEG) amplitude measures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Pain measure - Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</measure>
    <time_frame>baseline and 3 weeks</time_frame>
    <description>Measure of lower extremity pain and function in persons with knee OA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Experimental Pain measure - Temporal summation of punctate mechanical stimuli</measure>
    <time_frame>baseline and 3 weeks</time_frame>
    <description>Quantitative sensory testing measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Level of Distress measure - Perceived Stress Scale</measure>
    <time_frame>baseline and 3 weeks</time_frame>
    <description>Measure of perceived stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Affect Measure - Positive and Negative Affect Schedule (PANAS)</measure>
    <time_frame>baseline and 3 weeks</time_frame>
    <description>Measure of positive and negative affect.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Recall and Recognition measures - Hopkins Verbal Learning Test (HVLT)</measure>
    <time_frame>baseline and 3 weeks</time_frame>
    <description>Measure of verbal learning/memory</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain</condition>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For sessions 2 through 4, maintain normal eating patterns.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose Administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent Fasting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose Administration</intervention_name>
    <description>For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.</description>
    <arm_group_label>Glucose Administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intermittent Fasting</intervention_name>
    <description>For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).</description>
    <arm_group_label>Intermittent Fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Normal food intake</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with chronic knee osteoarthritis pain

        Exclusion Criteria:

          -  Concurrent medical condition that could confound outcome measures or limit the
             ability to participate completely in the protocol including: neurological conditions
             (Parkinson's disease, multiple sclerosis, and/or seizures)

          -  History of a head injury or stroke

          -  Diabetes

          -  Mental health issues resulting in hospitalization or outpatient treatment in the past
             year, and/or psychotropic medication use

          -  Current issue or history of treatment for alcohol or other substance abuse

          -  Cognitive function &lt; or = 22 on the Mini-Mental Status Exam

          -  Pregnancy

          -  A baseline fasting blood sugar (plasma glucose &gt; 7mmol/L) or persisting blood
             pressure &gt;150/95.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Sibille, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John G Marks, DHSc</last_name>
    <phone>352-273-5983</phone>
    <email>optimize@aging.ufl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Aging</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John G Marks, DHSc</last_name>
      <phone>352-273-5983</phone>
      <email>optimize@aging.ufl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Smith MA, Riby LM, Eekelen JA, Foster JK. Glucose enhancement of human memory: a comprehensive research review of the glucose memory facilitation effect. Neurosci Biobehav Rev. 2011 Jan;35(3):770-83. doi: 10.1016/j.neubiorev.2010.09.008. Epub 2010 Sep 29.</citation>
    <PMID>20883717</PMID>
  </reference>
  <reference>
    <citation>Hensch TK, Bilimoria PM. Re-opening Windows: Manipulating Critical Periods for Brain Development. Cerebrum. 2012 Jul;2012:11. Epub 2012 Aug 29.</citation>
    <PMID>23447797</PMID>
  </reference>
  <reference>
    <citation>Martin B, Mattson MP, Maudsley S. Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res Rev. 2006 Aug;5(3):332-53. Epub 2006 Aug 8. Review.</citation>
    <PMID>16899414</PMID>
  </reference>
  <reference>
    <citation>Cramer SC, Sur M, Dobkin BH, O'Brien C, Sanger TD, Trojanowski JQ, Rumsey JM, Hicks R, Cameron J, Chen D, Chen WG, Cohen LG, deCharms C, Duffy CJ, Eden GF, Fetz EE, Filart R, Freund M, Grant SJ, Haber S, Kalivas PW, Kolb B, Kramer AF, Lynch M, Mayberg HS, McQuillen PS, Nitkin R, Pascual-Leone A, Reuter-Lorenz P, Schiff N, Sharma A, Shekim L, Stryker M, Sullivan EV, Vinogradov S. Harnessing neuroplasticity for clinical applications. Brain. 2011 Jun;134(Pt 6):1591-609. doi: 10.1093/brain/awr039. Epub 2011 Apr 10.</citation>
    <PMID>21482550</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 14, 2017</lastchanged_date>
  <firstreceived_date>February 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuroplasticity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
